Literature DB >> 2166936

[Sensitivity of Aspergillus to ketoconazole and itraconazole using a standardized micromethod].

R Guinet1, H Marlier.   

Abstract

The standardized micromethod Mycototal is based on ready-to-use microtitration plates and the same culture medium for sensitivity testing of all antifungal agents. Since the method was very reproducible for yeasts it was applied for the determination of minimal inhibitory concentrations of Aspergillus to itraconazole and ketoconazole. Again the reproducibility for itraconazole was excellent since for 19 strains tested two times 18 showed no more than two dilutions different results and this was also observed for 6 strains over 7 tested 4 or 5 times. Over 31 strains tested belonging to different Aspergillus species, itraconazole was much more active than ketoconazole since for 2.5 mg/l all the strains were sensitive to itraconazole and only one to ketoconazole. Moreover no strains were sensitive to ketoconazole for 0.62 mg/l versus 9 strains sensitive to itraconazole. These results showed on one hand the reproducibility of the method and on the other hand the potency of itraconazole against Aspergillus according to the literature and let us hope to a better chemotherapy of aspergillosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2166936

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  3 in total

1.  Evaluation of five commercial antifungal susceptibility testing systems.

Authors:  A Druetta; A Freydiere; R Guinet; Y Gille
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

2.  Primary lymph node invasive aspergillosis.

Authors:  A Mazzoni; M Ferrarese; R Manfredi; A Facchini; C Sturani; A Nanetti
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

3.  Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.

Authors:  Lynn Purkins; Nolan Wood; Katie Greenhalgh; Michael J Allen; Stuart D Oliver
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.